ClinicalTrials.gg
TerminatedNCT03547154Updated Aug 12, 2019Results posted

Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

A Phase 2/3 interventional study of Pegylated interferon alfa-2b and Interferon alfa-2b in Chronic Myelogenous Leukemia, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-08-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 19 years 7 months after the study started (first participant enrolled Oct 1998, registered May 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
344
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The primary purpose of this study is to compare the efficacy of polyethylene glycol (PEG; pegylated) interferon alfa-2b (PEG Intron, C98026) versus interferon alfa-2b (Intron® A) in the treatment of participants with newly diagnosed CML.

02

Conditions studied

  • Chronic Myelogenous Leukemia
03

In context

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

This study's enrollment of 344 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has chronic phase CML diagnosed within 3 months prior to study enrollment
  • Has chronic phase CML positive for Ph\^1 as confirmed by cytogenetic studies, performed by a central laboratory
  • Has count >/= 50,000/microl
  • Has >/= 9.0 g/dL
  • Has WBC count >/=2000/microl but \</= 50,000/microl
  • Has adequate hepatic and renal function, as defined by the following parameters obtained within 14 days prior to initiation of study treatment

    • serum glutamic oxaloacetic transaminase () \<2 times upper limit of laboratory normal ()
    • serum glutamic pyruvic transaminase SGPT \<2 times upper ULN
    • serum \<2 times ULN
    • serum creatinine \<2.0 mg/dL
  • Is fully recovered from any prior major surgery and must be at least 4 weeks postoperative
  • Has Performance Status of 0-2
  • Has signed a written, voluntary before study entry, is willing to participate in this study, and is willing to complete all follow-up assessments

Exclusion criteria

Exclusion Criteria:

  • Has accelerated phase CML as defined by any of the following criteria.

    • peripheral blood myeloblasts >/=15%
    • peripheral blood basophils >/= 20%
    • peripheral blood myeloblasts plus promyelocytes >/=30%
    • \<100,000/microl, unrelated to therapy
  • Has blastic phase CML (30% myeloblasts in peripheral blood or bone marrow)
  • Is a candidate for and is planning to receive allogeneic, syngeneic, or bone marrow transplantation within the next 12 months
  • Has received prior treatment for their CML, except for hydroxyurea (collection of stem cells without using high dose chemotherapy for mobilization is acceptable)
  • Has severe cardiovascular disease (i. e., arrhythmias requiring chronic treatment, congestive heart failure [ (NYHA) Class III or IV], or symptomatic ischemic heart disease)
  • Has a history of a neuropsychiatric disorder requiring hospitalization
  • Has thyroid dysfunction not responsive to therapy
  • Has uncontrolled diabetes mellitus
  • Has a history of seropositivity for
  • Has active and/or uncontrolled infection, including active hepatitis
  • Has a medical condition requiring chronic systemic
  • Has a history of prior within the last 5 years, except for surgically cured non-melanoma skin cancer, or cervical carcinoma in situ
  • Has received any experimental therapy within 30 days prior to enrollment in this study
  • Is known to be actively abusing alcohol or drugs
  • Is pregnant, nursing, or of and is not practicing an effective means of
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
344 participants (actual)

Study arms

  • Experimental
    Pegylated interferon alfa-2b

    Participants received pegylated interferon alfa-2b (PEG Intron) at a dose of 6.0 microg/kg, administered weekly by subcutaneous (SC) injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the white blood cell (WBC) count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.

    Biological: Pegylated interferon alfa-2b

  • Active comparator
    Interferon alfa-2b

    Participants received interferon alfa-2b (Intron\^® A), recombinant for injection, at a dose of 5 million international units (MIU)/m\^2, administered daily by SC injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the WBC count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.

    Biological: Interferon alfa-2b

Interventions

  • Weekly SC injection of pegylated interferon alfa-2b, 6.0 microg/kg

    Also known as: PEG Intron

  • Daily SC injection of interferon alfa-2b, 5 MIU/m\^2

    Also known as: INTRON^® A

06

What researchers measure

Primary outcomes

  1. Number of Participants With Cytogenetic Responses to PEG Intron and INTRON A at 12 Months

    Cytogenetic response (CR) was defined by the degree of suppression of Philadelphia chromosome (Ph\^1) achieved during study treatment. For all participants continuing treatment after study conclusion, cytogenetic assessments were conducted locally as per standard of care. Determination of CR at 12 months were based on cytogenetic analysis of bone marrow aspirate samples. The CR criteria were based on the percentage (%) of PH\^1-positive cells during study treatment. Protocol-defined CR criteria were Complete Response (0%), Partial Response (1-34%), Minor Response (35-90%), or No Response (\>90%). Data for the analysis population was based on the intent-to-treat principle. Participants who were treatment failures at 6 months were considered cytogenetic non-responders. Recording of CR was independent of hematologic responses.

    Time frame: Up to 12 months

Secondary outcomes

  1. Number of Participants With Cytogenetic Response (CR) to PEG Intron and Intron A at 6 Months

    Cytogenetic response (CR) at 6 months, as at 12 months, was defined by the degree of suppression of Philadelphia chromosome (Ph\^1) achieved during study treatment. The determination of CR at 6 months was based on cytogenetic analysis of bone marrow aspirate samples. The CR criteria were based on the percentage (%) of PH\^1-positive cells during study treatment. Protocol-defined CR criteria were Complete (0%), Partial (1-34%), Minor (35-90%), or No Response (\>90%). Data for the analysis population was based on the intent-to-treat principle. Participants who were treatment failures at 6 months were considered cytogenetic non-responders. Recording of CR was independent of hematologic responses.

    Time frame: 6 months

  2. Number of Participants With Hematologic Responses to PEG Intron and Intron A at 6 Months

    Hematologic response at 6 months was assessed, while the hematologic response was measured at 3, 6, 9 and 12 months during the first year of study treatment. To be considered a hematologic responder a participant must have met all of the following criteria for a minimum of 28 days: WBC count \<10,000/μL; platelet count \<450,000/L; normal differential count in peripheral blood (manual differential count); no palpable spleen. Participants achieving a complete hematologic response at 3 months had the cytogenetic response evaluated at 3 months as well. Participants who achieved a complete hematologic response by 6 months continued treatment for another 6 months. Participants who failed to achieve a complete hematologic response after 6 months of treatment were considered treatment failures, and further treatment for this group was at the discretion of the treating physician. Participants may have continued to receive their assigned study medication for an additional 6 months.

    Time frame: 6 months

  3. Number of Participants With Overall Survival

    Participants were followed for survival; those who did not achieve a major cytogenetic response were discontinued from the study. For participants who completed 1 year of study treatment and continued to Year 2 and beyond, survival and disease progression every 3 months were assessed, and serious adverse events (SAEs) were reported. Participants were followed until resolution of any drug-related nonserious adverse event, and any SAE occurring while on the study or within 30 days of last dose of study drug. Participant death during survival follow-up was reported to the drug safety unit of the Sponsor. Each participant (whether discontinued or still on treatment) was followed every 3 months for survival and disease progression information. Overall survival was analyzed using the log-rank statistic, and the hazard ratio (HR) and 95% confidence interval (CI) for the HR were obtained using Cox's proportional hazards model.

    Time frame: Up to 2 years (24 months), and beyond

07

Results

Posted Aug 12, 2019
Limitations and caveats
AE Preferred Terms were converted from WHO-ART dictionary to the MedDRA version 10.0

Participant flow

Participant flow — Overall Study
MilestoneINTRON A (Interferon Alfa-2b)PEG Intron (Pegylated Interferon Alfa-2b)
Started173171
Completed5055
Not completed123116
Withdrew: Disease progression/recurrence614
Withdrew: Adverse event2631
Withdrew: Protocol violation61
Withdrew: Physician decision43
Withdrew: Insufficient therapeutic response1310
Withdrew: Withdrawal by subject106
Withdrew: Not selected01
Withdrew: Continued treatment beyond 12 mo.5850

Outcome measures

PrimaryNumber of Participants With Cytogenetic Responses to PEG Intron and INTRON A at 12 Months

Cytogenetic response (CR) was defined by the degree of suppression of Philadelphia chromosome (Ph\^1) achieved during study treatment. For all participants continuing treatment after study conclusion, cytogenetic assessments were conducted locally as per standard of care. Determination of CR at 12 months were based on cytogenetic analysis of bone marrow aspirate samples. The CR criteria were based on the percentage (%) of PH\^1-positive cells during study treatment. Protocol-defined CR criteria were Complete Response (0%), Partial Response (1-34%), Minor Response (35-90%), or No Response (\>90%). Data for the analysis population was based on the intent-to-treat principle. Participants who were treatment failures at 6 months were considered cytogenetic non-responders. Recording of CR was independent of hematologic responses.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
Number of Participants With Cytogenetic Responses to PEG Intron and INTRON A at 12 Months
ParticipantsINTRON A (Interferon Alfa-2b)PEG Intron (Pegylated Interferon Alfa-2b)
Complete Response1313
Partial Response3526
Minor Respnse3124
No Respnse1525
Discontinued or No Hematologic CR at Month 67883
Participants with Missing Data10
Statistical analysis
  • INTRON A (Interferon Alfa-2b) vs PEG Intron (Pegylated Interferon Alfa-2b) · Fisher Exact · p = 0.322 (Analysis of Major Response)Missing data considered failures
SecondaryNumber of Participants With Cytogenetic Response (CR) to PEG Intron and Intron A at 6 Months

Cytogenetic response (CR) at 6 months, as at 12 months, was defined by the degree of suppression of Philadelphia chromosome (Ph\^1) achieved during study treatment. The determination of CR at 6 months was based on cytogenetic analysis of bone marrow aspirate samples. The CR criteria were based on the percentage (%) of PH\^1-positive cells during study treatment. Protocol-defined CR criteria were Complete (0%), Partial (1-34%), Minor (35-90%), or No Response (\>90%). Data for the analysis population was based on the intent-to-treat principle. Participants who were treatment failures at 6 months were considered cytogenetic non-responders. Recording of CR was independent of hematologic responses.

Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Participants With Cytogenetic Response (CR) to PEG Intron and Intron A at 6 Months
ParticipantsINTRON A (Interferon Alfa-2b)PEG Intron (Pegylated Interferon Alfa-2b)
Complete Response: 0% Ph+73
Partial Response: 1-34% Ph+1923
Minor Response: 35-90% Ph+5137
No Response: >90% Ph+4861
Participant with Missing Data4847
Statistical analysis
  • INTRON A (Interferon Alfa-2b) vs PEG Intron (Pegylated Interferon Alfa-2b) · Fisher Exact · p = >0.999 (Analysis of Major Response)Missing data considered failures
SecondaryNumber of Participants With Hematologic Responses to PEG Intron and Intron A at 6 Months

Hematologic response at 6 months was assessed, while the hematologic response was measured at 3, 6, 9 and 12 months during the first year of study treatment. To be considered a hematologic responder a participant must have met all of the following criteria for a minimum of 28 days: WBC count \<10,000/μL; platelet count \<450,000/L; normal differential count in peripheral blood (manual differential count); no palpable spleen. Participants achieving a complete hematologic response at 3 months had the cytogenetic response evaluated at 3 months as well. Participants who achieved a complete hematologic response by 6 months continued treatment for another 6 months. Participants who failed to achieve a complete hematologic response after 6 months of treatment were considered treatment failures, and further treatment for this group was at the discretion of the treating physician. Participants may have continued to receive their assigned study medication for an additional 6 months.

Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Participants With Hematologic Responses to PEG Intron and Intron A at 6 Months
ParticipantsINTRON A (Interferon Alfa-2b)PEG Intron (Pegylated Interferon Alfa-2b)
Complete Response9891
Treatment Failure4452
Missing3128
Statistical analysis
  • INTRON A (Interferon Alfa-2b) vs PEG Intron (Pegylated Interferon Alfa-2b) · Fisher Exact · p = 0.588 (Analysis of Complete Response)Missing data considered failures
SecondaryNumber of Participants With Overall Survival

Participants were followed for survival; those who did not achieve a major cytogenetic response were discontinued from the study. For participants who completed 1 year of study treatment and continued to Year 2 and beyond, survival and disease progression every 3 months were assessed, and serious adverse events (SAEs) were reported. Participants were followed until resolution of any drug-related nonserious adverse event, and any SAE occurring while on the study or within 30 days of last dose of study drug. Participant death during survival follow-up was reported to the drug safety unit of the Sponsor. Each participant (whether discontinued or still on treatment) was followed every 3 months for survival and disease progression information. Overall survival was analyzed using the log-rank statistic, and the hazard ratio (HR) and 95% confidence interval (CI) for the HR were obtained using Cox's proportional hazards model.

Time frame:
Up to 2 years (24 months), and beyond
Reported as:
Count of participants · Participants
Number of Participants With Overall Survival
ParticipantsINTRON A (Interferon Alfa-2b)PEG Intron (Pegylated Interferon Alfa-2b)
Deaths1517
Survivors158154
Statistical analysis
  • INTRON A (Interferon Alfa-2b) vs PEG Intron (Pegylated Interferon Alfa-2b) · Cox proportional hazard: 0.859 · 95% CI 0.429 to 1.721Overall survival was analyzed using the log-rank statistic. The HR and 95% CI for the HR were obtained using Cox's proportional hazards model.

Adverse events

Collected over Up to One Year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
INTRON A, 5 MIU/m^2 Daily15/173 (8.7%)62/173 (35.8%)170/173 (98.3%)
PEG-Intron, 6.0 mcg/kg Weekly17/171 (9.9%)74/171 (43.3%)168/171 (98.2%)
Most frequent serious events
Showing 10 of 145
Most frequent serious events
EventINTRON A, 5 MIU/m^2 DailyPEG-Intron, 6.0 mcg/kg Weekly
PYREXIAGeneral disorders6/1737/171
ARTHRALGIAMusculoskeletal and connective tissue disorders3/1737/171
NAUSEAGastrointestinal disorders3/1736/171
CHEST PAINGeneral disorders3/1735/171
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders1/1735/171
ANAEMIABlood and lymphatic system disorders0/1734/171
DIZZINESSNervous system disorders2/1734/171
DYSPNOEARespiratory, thoracic and mediastinal disorders3/1734/171
THROMBOCYTOPENIABlood and lymphatic system disorders4/1733/171
VOMITINGGastrointestinal disorders4/1733/171
Most frequent other events
Showing 10 of 101
Most frequent other events
EventINTRON A, 5 MIU/m^2 DailyPEG-Intron, 6.0 mcg/kg Weekly
PYREXIAGeneral disorders133/173141/171
HEADACHENervous system disorders128/173132/171
CHILLSGeneral disorders108/173115/171
NAUSEAGastrointestinal disorders101/173111/171
MYALGIAMusculoskeletal and connective tissue disorders109/17399/171
DIARRHOEAGastrointestinal disorders95/173104/171
FATIGUEGeneral disorders105/173103/171
ANOREXIAMetabolism and nutrition disorders86/173103/171
ASTHENIAGeneral disorders81/17394/171
ARTHRALGIAMusculoskeletal and connective tissue disorders79/17387/171

Baseline characteristics

Age, Continuous
Age, Continuous(Years)INTRON A (Interferon Alfa-2b)PEG Intron (Pegylated Interferon Alfa-2b)Total
Mean51.6 ± 13.451.9 ± 12.851.7 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)INTRON A (Interferon Alfa-2b)PEG Intron (Pegylated Interferon Alfa-2b)Total
Female6775142
Male10696202
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 1998 to primary completion in Feb 2001, 27 months.

Results were first posted in Aug 2019, 18 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2018
First posted
Jun 6, 2018
StartActual
Oct 22, 1998
Primary completionActual
Feb 20, 2001
CompletionActual
Feb 20, 2001
Results first posted
Aug 12, 2019
Last update
Aug 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03547154
Responsible party
Sponsor
First posted
Jun 6, 2018
Start date
Oct 22, 1998
Primary completion
Feb 20, 2001
Completion
Feb 20, 2001
Results posted
Aug 12, 2019
Last update
Aug 12, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion